New hope for hemophilia b: trial tests Long-Acting clotting factor in chinese patients

NCT ID NCT05365217

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a medicine called nonacog beta pegol (N9-GP) in 30 Chinese men with moderate to severe hemophilia B. The medicine is injected into a vein to help blood clot and prevent or treat bleeding episodes. The trial lasted about 12-16 months and checked how well the medicine worked and how safe it was.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nonacog beta pegol (a clotting factor IX medicine)
What this could lead to: If successful, this could provide a safe and effective option for Chinese patients with hemophilia B to control and prevent bleeding episodes.
What could go wrong: This is a small, completed phase 3 trial with only 30 participants, so results may not apply to all patients. The medicine is already approved elsewhere, but its long-term safety and effectiveness in this specific population need confirmation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMOPHILIA B

Contacts and locations

Locations

Beijing Children's Hospital, Capital Medical University

Beijing, Beijing Municipality, 100045, China
Children's Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310052, China
Fujian Medical University Union Hospital-Hematology

Fuzhou, Fujian, 350001, China
Henan Cancer Hospital-Hematology

Zhengzhou, Henan, 450003, China
Institute of Hematology and Blood Diseases Hospital, Tianjin-Hematology

Tianjin, Tianjin Municipality, 300020, China
Jinan Central Hospital

Jinan, Shandong, 250013, China
Nanfang Hospital, Southern Medical University-Haematology

Guangzhou, Guangdong, 510515, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
The Affiliated Hospital of Guizhou Medical University-Hematology

Guiyang, Guizhou, 550004, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266000, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266555, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The Second Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, 650101, China
Tongji Hospital, Tongji Medical College of HUST-Hematology

Wuhan, Hubei, 430030, China
Xiangya Hospital Central-South University

Changsha, Hunan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.